A Phase 2, Prospective, Multicenter, Double-blind, Randomized Study of Saroglitazar Magnesium 1 mg, 2 mg or 4 mg Versus Placebo in Patients With Nonalcoholic Fatty Liver Disease and/or Nonalcoholic Steatohepatitis
Phase of Trial: Phase II
Latest Information Update: 26 Apr 2017
At a glance
- Drugs Saroglitazar (Primary)
- Indications Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
- Focus Therapeutic Use
- Acronyms EVIDENCES-II
- Sponsors Zydus Discovery DMCC
- 10 Mar 2017 Planned initiation date changed from 1 Feb 2017 to 1 Mar 2017.
- 31 Oct 2016 Status changed from not yet recruiting to recruiting, as per Zydus Cadila media release.
- 06 Jun 2016 New trial record